Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

clarkhealthcommunications

- PMLiVE

Achieving communication excellence by targeting the right channel at the right time

By Danny Buckland It’s been a turbulent term for the pharmaceutical industry and the end of year reports make for patchy reading as the pandemic’s forced syllabus changes created a...

- PMLiVE

WHO, UNICEF and UNAIDS launch global alliance to end AIDS in children by 2030

Globally only 52% of children living with HIV are on life-saving treatment, compared to 76% of adults receiving antiretrovirals

- PMLiVE

Alzheimer’s Research UK calls for government action to address inequalities in dementia risk

The call comes as researchers presented findings demonstrating a link between socio-economic deprivation and higher dementia risk

- PMLiVE

Janssen’s Stelara approved by FDA for psoriatic arthritis in paediatric patients

Active psoriatic arthritis affects 5-8% of children and adolescents with chronic inflammatory arthritis

- PMLiVE

Arcutis receives FDA approval for steroid-free plaque psoriasis treatment

Zoryve is the first and only PDE4 inhibitor approved for plaque psoriasis

- PMLiVE

Boehringer Ingelheim and QUANTRO Therapeutics partner to develop drug candidates

The collaboration aims to offer a long-term strategy to provide breakthrough cancer treatments

- PMLiVE

Achieving communication excellence by targeting the right channel at the right time

By Danny Buckland

- PMLiVE

Innovation through collaboration – the importance of partnerships

By Mario Ippolito

- PMLiVE

‘Who moved my cheese?’

By Harriet Coady

- PMLiVE

Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection

Subcutaneously administering Tecentriq reduced the time needed for treatment compared to standard IV infusion

regeneron headquarters

Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV

The drug was taken off the US market in January due to it being ‘highly unlikely’ to be active against the Omicron variant

- PMLiVE

AstraZeneca and Innate Pharma to end study on immuno-oncology drug monalizumab

The INTERLINK-1 study assessed the combination drug candidate to treat patients with head and neck cancer

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links